Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding

PharmacoEconomics

Volumn 28, Issue 3, 2010, Pages 217-230

  Barkun, Alan N ^a   Adam, Viviane ^a   Sung, Joseph J Y ^b   Kuipers, Ernst J ^c   Mössner, Joachim ^d   Jensen, Dennis ^e   Stuart, Robert ^f   Lau, James Y ^b   Nauclér, Emma ^g   Kilhamn, Jan ^g   Granstedt, Helena ^g   Liljas, Bengt ^g   Lind, Tore ^g  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f GLASGOW ROYAL INFIRMARY   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HEMOSTASIS; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; PATIENT CARE; PATIENT SELECTION; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SPAIN; SWEDEN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ADMINISTRATION, ORAL; ANTI-ULCER AGENTS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HEMOSTASIS, ENDOSCOPIC; HUMANS; INFUSIONS, INTRAVENOUS; MODELS, ECONOMIC; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPAIN; SWEDEN; TREATMENT OUTCOME; UNITED STATES;

EID: 77149148427     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11531480-000000000-00000     Document Type: Article

References (55)

1. British Society of Gastroenterology Endoscopy Committee. Non-variceal upper gastrointestinal haemorrhage: guidelines. Gut 2002 Oct; 51 Suppl. 4: iv1-6
2. Vreeburg EM, Snel P, de Bruijne JW, et al. Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol 1997 Feb; 92 (2): 236-243
3. Blatchford O, Davidson LA, Murray WR, et al. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 1997 Aug 30; 315 (7107): 510-514
4. Kapsoritakis AN, Ntounas EA, Makrigiannis EA, et al. Acute upper gastrointestinal bleeding in Central Greece: the role of clinical and endoscopic variables in bleeding outcome. Dig Dis Sci 2009 Feb; 54 (2): 333-341
5. Theocharis GJ, Thomopoulos KC, Sakellaropoulos G, et al. Changing trends in the epidemiology and clinical outcome of acute upper gastrointestinal bleeding in a defined geographical area in Greece. J Clin Gastroenterol 2008 Feb; 42 (2): 128-133
6. van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol 2003 Jul; 98 (7): 1494-1499
7. Lewis JD, Bilker WB, Brensinger C, et al. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Am J Gastroenterol 2002 Oct; 97 (10): 2540-2549
8. Adam V, Barkun AN. Estimates of costs of hospital stay for variceal and nonvariceal upper gastrointestinal bleeding in the United States. Value Health 2008 Jan-Feb; 11 (1): 1-3
9. Targownik LE, Nabalamba A. Trends in management and outcomes of acute nonvariceal upper gastrointestinal bleeding: 1993-2003. Clin GastroenterolHepatol 2006 Dec; 4 (12): 1459-1466
10. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ 1995 Jul 22; 311 (6999): 222-226
11. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004 Jul; 99 (7): 1238-1246
12. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995 Feb; 90 (2): 206-210
13. Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994 Sep 15; 331 (11): 717-727
14. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003 Nov 18; 139 (10): 843-857
15. Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Metaanalysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005 Mar 15; 21 (6): 677-686
16. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor therapy for peptic ulcer bleeding: Cochrane collaboration meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 Mar; 82 (3): 286-296
17. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia. A post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005 May 1; 21 (9): 1055-1061
18. Sung JJY, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized controlled trial. Ann Intern Med 2009; 150 (7): 455-464
19. Al-Sabah S, Barkun AN, Herba K, et al. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2008 Apr; 6 (4): 418-425
20. Healthcare Cost and Utilization Project. Nationwide inpatient sample 2002 [online]. Available fromURL: http://www. hcup-us.ahrq.gov/nisoverview.jsp [Accessed 2008 Jul 1]
21. Spiegel BM, Dulai GS, Lim BS, et al. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage. Clin Gastroenterol Hepatol 2006 Aug; 4 (8): 988-997
22. Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from nonsteroidal antiinflammatory drugs: costeffectiveness of competing strategies in varying risk groups. Arthritis Rheum 2005 Apr 15; 53 (2): 185-197
23. Gerson L, Lin OS. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 2007 Mar; 5 (3): 319-325
24. Red Book 2006. Pharmacy's fundamental reference (Red Book drug topics). Montvale (NJ): Thomson PDR, 2006
25. Swedish Association of Local Authorities and Regions (SALAR) [online]. Available from URL: http://www.skl.se [Accessed 2008 May 12]
26. Dental and Pharmaceutical Benefits Agency (TLV, formerly LFN). Kostnadseffektiva läkemedel [online]. Available from URL: http://www.tlv.se [Accessed 2008 May 12]
27. Decreto 83/2004, do 15 de abril, polo que se establecen as tarifas dos servizos sanitarios prestados nos centros dependentes do Servizo Galego de Saú de e nas fundació ns pú blicas sanitarias. Diario Oficial de Galicia 2004 May 4; No.85: 6235-6249
28. Decreto 272/2005, de 27 de diciembre, por el que se establecen y regulan los precios pú blicos corespondientes a los servicios sanitarios del Servicio Extremeño de Salud. Diario Oficial de Extremadura 2005 Dec 31; No.150: 18342-18365
29. Orden SLT/483/2005, de 15 de diciembre, por la que se regulan los supuestos y conceptos facturables y se aprueban los precios pú blicos correspondientes a los servicios que presta el Instituto Catalán de la Salud. Diario Oficial de la Generalidad de Cataluña 2005 Dec 30; No.4540
30. Resolució n de 16-01-2006, del Sescam, sobre precios a aplicar por sus centros sanitarios a terceros obligados al pago o a los usuarios sin derecho a asistencia sanitaria. Diario Oficial de Castilla La Mancha 2006 Jan 26; No.19: 1365-1367
31. Resolución de 28 de octubre de 2005, del Presidente de la Gerencia Regional de Salud, de revisión de las condiciones económicas aplicables en el año 2005, a la perstación de servicios de asistencia sanitaria concertada en el ámbito de la Gerencia Regional de Salud. BOCyL 2005 Nov 7; No.214
32. Orden de 7 de abril de 2006, por la que se revisan las condiciones econó micas aplicables a la asistencia sanitaria prestada con medios ajenos en el ejercicio 2005. Boletín Oficial de Canarias 2006 Apr; No.76: 7403-7424
33. Decreto 34/2006 de 19 de abril, por el que se establecen los precios pú blicos por la prestación de los servicios y actividades de naturaleza sanitaria de los centros dependientes del Servicio de Salud del Principado de Asturias. Boletín Oficial del Principado de Asturias 2006 May 9; No.105: 9353-9358
34. Ministerio de Sanidad y Consumo. Cifras de referencia nacional de los Grupos Relacionados por el Diagnó stico (GRD). Pesos Españoles y Costes para el SNS. Año 2005 [online]. Available from URL: http://www.msc.es/estad Estudios/estadisticas/docs/pesosEspGRD-ApV18Ano2005. pdf [Accessed 2008 May 1]
35. Orden 234/2005, de 23 de febrero, del Consejero de Sanidad y Consumo, por la que se fijan los precios pú blicos por la prestacio ́n de los servicios y actividades de naturaleza sanitaria de la Red de Centros de la Comunidad Autónoma. Boletín Oficial de la Comunidad de Madrid 2005 Mar 8; No.56
36. Hospital Clinic i Provincial de Barcelona. Barcelona: Tarifari de, 1997
37. Hospital de la Santa Creu i Sant Pau. Barcelona: Memoria, 1992
38. Ministry of Health. Nomenclator of medicines [online]. Available from URL: http://www.msc.es/profesionales/ farmacia/nomenclatorDI.htm [Accessed 2008 May 1]
39. General Spanish Council of Pharmacists. Pharmaceutical Association [online]. Available from URL: http://www. portalfarma.com [Accessed 2008 May 1]
40. Barkun AN, Herba K, Adam V, et al. The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding. Aliment Pharmacol Ther 2004 Jul 15; 20 (2): 195-202
41. Barkun AN, Herba K, Adam V, et al. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004 Mar 1; 19 (5): 591-600
42. Department of Health & Human Services. Centers for Medicare & Medicaid Services [online]. Available from URL: http://www.cms.hhs.gov/ [Accessed 2009 Nov 23]
43. Lee KK, You JH, Wong IC, et al. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc 2003 Feb; 57 (2): 160-164
44. Spiegel BM, Ofman JJ, Woods K, et al. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. Am J Gastroenterol 2003 Jan; 98 (1): 86-97
45. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: proton-pump inhibitor treatment for ulcer bleeding reduces transfusion requirements and hospital stay. Results from the Cochrane Collaboration. Aliment Pharmacol Ther 2005 Aug 1; 22 (3): 169-174
46. Lau JY, Leung WK, Wu JC, et al. Omeprazole before endoscopy in patients with gastrointestinal bleeding. N Engl J Med 2007 Apr 19; 356 (16): 1631-1640
47. Dorward S, Sreedharan A, Leontiadis GI, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2006; (4): CD005415
48. Enns RA, Gagnon YM, Rioux KP, et al. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003 Jan; 17 (2): 225-233
49. Tsoi KK, Lau JY, Sung JJ. Cost-effectiveness analysis of high-dose omeprazole infusion before endoscopy for patients with upper-GI bleeding. Gastrointest Endosc 2008 Jun; 67 (7): 1056-1063
50. Barkun AN. Should every patient with suspected upper GI bleeding receive a proton pump inhibitor while awaiting endoscopy? Gastrointest Endosc 2008 Jun; 67 (7): 1064-1066
51. Sung JJY, Barkun A, Kuipers EJ, et al. Letter of reply to all correspondents [online]. Available fromURL: http://www.an nals.org/cgi/eletters/ 150/7/455#114442 [Accessed 2009 Oct 1]
52. Hearnshaw S, Logan R,MurphyM, et al. Results of the UK audit of 6750 patients with acute upper gastrointestinal haemorrhage. Gut. In press
53. Erstad BL. Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding. Crit Care Med 2004 Jun; 32 (6): 1277-1283
54. Spiegel BM, Ofman JJ, Woods K, et al. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. Am J Gastroenterol 2003 Jan; 98 (1): 86-97
55. Bala MV, Zarkin GA. Are QALYs an appropriate measure for valuing morbidity in acute diseases? Health Econ 2000 Mar; 9 (2): 177-180